Vasoretic

Quick links to important sections

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Vasoretic

Property Description
Active ingredient Enalapril Maleate, Hydrochlorothiazide (HCTZ)
Form Oral Tablet
Pharmacological class ACE Inhibitor and Thiazide Diuretic (Antihypertensive Agents)
General purpose Sustained control of high blood pressure
Origin Synthetic

What Type of Antihypertensive Agent is Vasoretic?

Vasoretic is the trade name for a prescription-only, fixed-dose combination product containing the active ingredients Enalapril Maleate and Hydrochlorothiazide (HCTZ), and is clinically recognized as an antihypertensive agent. This medication is presented as an oral tablet and combines two distinct categories of blood pressure-lowering medications into a single unit. This design ensures simultaneous delivery of both agents, representing a therapeutic strategy for managing complex hypertension in adult patients. As a product of synthetic origin, Vasoretic modulates key physiological systems involved in regulating vascular pressure and fluid balance.


Composition: The Dual-Mechanism Advantage

Vasoretic is composed of two primary active chemical substances from complementary pharmacological classes. Enalapril Maleate is the component classified as an Angiotensin-Converting Enzyme (ACE) Inhibitor, which acts by promoting vasorelaxation in the blood vessels. Hydrochlorothiazide is the second component, a type of diuretic belonging to the thiazide diuretic class. As a combination of an ACE Inhibitor and a diuretic, this fixed-dose design allows for a dual-mechanism approach that simultaneously addresses both vascular tone and circulating fluid volume.


General Purpose: How Does the Combination Benefit Blood Pressure?

This combination is designed to provide a strategy for blood pressure control through the synergy of two different physiological actions. The Enalapril component lowers pressure by widening blood vessels and reducing systemic resistance, while the Hydrochlorothiazide component facilitates the reduction of overall fluid volume in the bloodstream via diuresis. By combining volume reduction with vasodilation, the medication offers a sustained approach for managing and maintaining controlled blood pressure levels than either component used alone.

Regulatory References

  1. Enalapril/Hydrochlorothiazide (Vaseretic): Uses, Side Effects, Interactions, Pictures, Warnings & Dosing

What side effects are possible with Vasoretic?

Possible Side Effects and Safety Information

The official safety information for Vasoretic (enalapril and hydrochlorothiazide) documents adverse reactions and warnings across several categories, with some events being common and others rare but serious.


Serious and Clinically Significant Adverse Reactions

The product label includes a Black Box Warning regarding use during pregnancy. Use during the second and third trimesters can cause injury and even death to the developing fetus, and the medication must be discontinued as soon as pregnancy is detected.

Serious allergic reactions include angioedema (swelling of the face, lips, tongue, larynx, or intestines) which may be fatal and requires immediate attention. Other serious effects include hepatic failure, renal failure, and severe skin reactions such as Stevens-Johnson syndrome.

Commonly Documented Adverse Reactions

Adverse reactions reported as common in clinical trials include dizziness, headache, fatigue, and cough.


Organ System and Population-Specific Risks

  • Electrolyte Imbalance: Potential for changes in serum electrolytes, including hyperkalemia (high potassium) and hyponatremia (low sodium), requiring baseline and periodic monitoring.
  • Non-Melanoma Skin Cancer (NMSC): The hydrochlorothiazide component is associated with a cumulative, dose-dependent increased risk of basal cell carcinoma (BCC) and squamous cell carcinoma (SCC), particularly with prolonged use (e.g., three years or more).
  • Ocular Effects: The drug is associated with rare, acute reactions involving the eye, such as acute transient myopia and secondary angle-closure glaucoma.
  • Contraindications: Vasoretic is contraindicated in patients with a history of angioedema related to previous ACE inhibitor treatment, hereditary or idiopathic angioedema, anuria, and allergy to sulfonamide-derived drugs.

Overdose and Emergency Response

Vasoretic Overdose and when to seek help

Overdose Scope

The officially documented overdose presentations for Vasoretic (Enalapril Maleate/Hydrochlorothiazide) are primarily defined by two physiological effects: Profound Hypotension and Excessive Diuresis. Profound Hypotension, the most likely manifestation of the ACE inhibitor component, can lead to Bradycardia or Tachycardia. The diuretic component causes excessive fluid loss, resulting in volume depletion and critical electrolyte imbalance, specifically low serum potassium (Hypokalemia) and low sodium (Hyponatremia). These manifestations can lead to severe, life-threatening outcomes, including circulatory collapse (shock) and acute renal failure secondary to the extreme blood pressure drop.

Emergency Response and Monitoring

The regulatory mandate for suspected overdose is to seek immediate medical attention or contact a Poison Control Center or emergency room at once. This action is required regardless of symptom presence, but particularly if signs such as severe dizziness, fainting, or syncope occur. No specific antidote is known for the Enalapril component. Management is strictly symptomatic and supportive, aiming to reverse hypotension and fluid loss, often involving the intravenous infusion of normal saline. Continuous patient observation is required, alongside frequent monitoring of vital signs, serum electrolytes, and renal function to guide necessary corrective measures.

Therapeutic Uses of Vasoretic

What Vasoretic Treats: Main Uses and Benefits

The combination of enalapril and hydrochlorothiazide in Vasoretic is commonly used to help manage Essential Hypertension by addressing two physiological areas. This medication is used for this chronic condition, which is characterized by symptoms related to heightened physiological activity—namely, persistently high blood pressure readings.


Vasoretic is generally applicable for the long-term management of hypertension in adults. Its use is associated with contributing to the controlled lowering of persistently elevated blood pressure readings. The use is typically relevant in conditions characterized by periods of heightened symptoms (elevated pressure) or when the condition presents with systemic discomfort (vascular strain). It is applied in situations where additional management of discomfort is required beyond single-drug therapy.


Supporting Long-Term Organ Risk Management

Supporting a managed blood pressure level assists with managing symptoms linked to organ-specific functional stress (heart, brain, and kidneys). This ultimately supports general well-being during symptomatic phases and may assist with maintaining functional stability. The medication is used for managing Essential Hypertension and addressing uncontrolled blood pressure that requires a dual-modality approach.


Quick Fact: Relief for Uncontrolled Pressure
Vasoretic is commonly used to help with symptoms that create noticeable physiological strain and is applied in scenarios where additional management of discomfort is required beyond single-drug therapy.

Regulatory References

  1. NIH MedlinePlus Drug Information

Eligibility and Restrictions for Use

Who Can and Cannot Use Vasoretic?

The population eligibility for Vasoretic (Enalapril Maleate/Hydrochlorothiazide) is strictly defined by regulatory documents, which establish groups that must not use the medicine (contraindications) and those for whom use is restricted.

Contraindications (Must Not Use)

Condition / Population
History of angioedema (swelling) related to previous ACE inhibitor therapy.
Hereditary or idiopathic angioedema.
Anuria (inability to pass urine) or severe hepatic impairment.
Severe renal impairment (Creatinine clearance le 30 mL/min).
Second and third trimesters of pregnancy.
Concomitant use with Neprilysin Inhibitors or aliskiren (in patients with diabetes/renal impairment).

Restricted and Non-Recommended Use

Population Group Regulatory Status
Pediatric population (under 18 years) Not recommended; safety/efficacy not established.
First trimester of pregnancy Not recommended; discontinue immediately if detected.
Breastfeeding women Not recommended; components are excreted into human milk.
Moderate renal impairment Restricted; requires prior individual component titration.
Adults (18+), including Geriatrics Eligible for use in Essential Hypertension, but caution advised for age-related organ issues in older adults.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Official regulatory documents classify certain combinations with Vasoretic (Enalapril Maleate/Hydrochlorothiazide) as contraindicated due to the risk of severe interaction outcomes. Co-administration with Sacubitril-containing products is strictly prohibited due to the increased risk of angioedema. When switching between these agents, a mandatory 36-hour washout period is required.

Dual blockade of the Renin-Angiotensin System is officially restricted: the co-administration of Aliskiren is contraindicated specifically in patients with diabetes mellitus or those with renal impairment (GFR < 60 mL/min/1.73 m²).

Pharmacodynamic interactions require caution with agents that affect electrolytes or blood pressure. Combining Vasoretic with Potassium Supplements or potassium-containing salt substitutes increases the risk of hyperkalemia. The hydrochlorothiazide component is documented to reduce the renal clearance of Lithium, which can lead to increased serum lithium concentrations and the risk of lithium toxicity.

Non-medicinal substance constraints exist, as alcohol (ethanol) is documented to potentiate orthostatic hypotension. Additionally, Cholestyramine and Colestipol resins reduce the absorption of the hydrochlorothiazide component, which is a documented pharmacokinetic interaction.

Mechanism of Action

Vasoretic is a fixed-dose combination agent designed to modulate skeletal remodeling and calcium homeostasis.

The primary component, Alendronate, is a nitrogen-containing bisphosphonate that is preferentially internalized by osteoclasts. Within the osteoclast, Alendronate acts as a structural analog of pyrophosphate to inhibit the enzyme farnesyl pyrophosphate synthase (FPPS), a key enzyme in the mevalonate pathway.

Inhibition of FPPS prevents the prenylation of small GTPase signaling proteins essential for osteoclast cytoskeletal organization and membrane function. This mechanistic cascade ultimately leads to the inhibition of osteoclast activity and their subsequent apoptosis. This action decreases the rate of bone resorption at the cellular level.

The secondary component, Cholecalciferol (Vitamin D3), undergoes sequential hydroxylation to form the active metabolite, 1,25( OH)2 D3. This metabolite binds to the Vitamin D Receptor (VDR), a nuclear transcription factor, promoting the expression of proteins involved in intestinal calcium absorption. The combination thus targets both cellular bone remodeling (osteoclast activity) and systemic calcium influx (VDR activation).

Dosage and Administration Information

Vasoretic is administered orally as a fixed-dose combination tablet. The medication is used once daily, and the dose may be taken with or without food, establishing flexibility in the daily administration schedule.

This fixed-dose combination is not indicated for the initial treatment of essential hypertension. Its use is reserved for adult patients whose blood pressure is not adequately controlled with monotherapy of either enalapril or hydrochlorothiazide, or for those who have been stabilized on the individual components. This principle dictates that the fixed formulation is introduced only after a clinical determination of the individual requirements for each ingredient.

The standard adult regimen is generally one tablet once daily. The maximum daily dose for the combination should not exceed 20 mg of enalapril and 50 mg of hydrochlorothiazide. Dose adjustments, if necessary, are typically made in intervals of at least two to three weeks to assess the full effect of the hydrochlorothiazide component.

Specific administration constraints apply to certain patient groups. The safety and effectiveness have not been established in pediatric patients (under 18 years of age). Furthermore, the product is not recommended for patients with severe renal impairment (creatinine clearance less than 30 mL/min), as the thiazide diuretic component may become ineffective. If a dose is missed, the protocol involves taking the missed dose as soon as it is remembered, unless it is almost time for the next scheduled dose, in which case the missed dose is skipped; patients do not take a double dose to compensate.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Vasoretic

The clinical evidence for the combination of Enalapril and Hydrochlorothiazide (Vasoretic) is primarily derived from controlled trials and scientific reviews. Research focuses on how the medication affects key physiological markers and the study landscape highlights areas of certainty and ongoing research.


Evidence for Managing Essential High Blood Pressure

Studies exploring the use of this combination for managing essential hypertension largely consist of Randomized Controlled Trials (RCTs). These trials were designed to examine the blood pressure metrics for the combination in adults. Research examined outcomes related to physiological strain, specifically focusing on measured changes in blood pressure readings, typically observed over short to intermediate periods.

Findings from these trials describe patterns observed in blood pressure and monitored endpoints related to predefined blood pressure goals. Studies were designed to examine the additional blood pressure changes when combining both agents compared to monotherapy. However, the evidence is limited regarding the long-term impact of the fixed-dose combination specifically on major cardiovascular endpoints, as this area is largely evaluated by separate, multi-year trials of the individual drug classes.


Long-Term Research and Study Durability

The evidence base related to the durability and long-term metrics associated with blood pressure management is primarily drawn from large-scale, long-term RCTs and systematic reviews concerning the individual drug classes (ACE inhibitors and thiazide diuretics). These studies monitored high-risk populations over many years.

The inferences related to long-term cardiovascular metrics (such as stroke or heart attack) are primarily derived from the extensive long-term evidence of the drug's individual classes, and not from dedicated research on Vasoretic itself. Limited information is available from studies that follow the fixed-dose combination product specifically for these long-term endpoints.


Evidence in Specific Patient Populations

Research has explored the effects of the combination in certain adult subgroups, including older adults. Additionally, trials have explored racial and ethnic differences in patient response. Research indicates that while the ACE inhibitor component alone may have a varying response, the presence of the diuretic (HCTZ) in the combination was observed to be associated with similar blood pressure changes in both Black and non-Black hypertensive patients, contributing to observed patterns of response across these populations.

However, data for certain groups remain insufficient. Specifically, appropriate studies have not been performed to establish the safety or effects of this combination in the pediatric population (children).

Key Studies & References

  1. Mortality and Morbidity Among Individuals With Hypertension Receiving a Diuretic, ACE Inhibitor, or Calcium Channel Blocker: A Secondary Analysis of a Randomized Clinical Trial (ALLHAT follow-up)
  2. Enalapril and Hydrochlorothiazide: MedlinePlus Drug Information (Used for general context and pediatric data gap)

Frequently Asked Questions (FAQ)

Common questions about Vasoretic (FAQ)

Q: What is the main purpose of taking Vasoretic?

A: Official product information states that Vasoretic is indicated for the treatment of hypertension (high blood pressure). This fixed-dose combination is generally reserved for use in adult patients whose blood pressure is not adequately controlled by either of the individual components alone.

Q: Why is Vasoretic a combination of two different types of medicine?

A: The two components of the drug are combined because the reduction in blood pressure achieved by using both enalapril and hydrochlorothiazide is approximately additive. This suggests the effects are approximately additive.

Q: What does the ACE inhibitor component (enalapril) in Vasoretic do?

A: The enalapril component is an ACE inhibitor that works by inhibiting the angiotensin-converting enzyme. This action leads to decreased vasopressor activity, helping to relax blood vessels and lower blood pressure.

Q: What does the water pill component (hydrochlorothiazide) in Vasoretic do?

A: The hydrochlorothiazide component is a diuretic (a water pill) that affects electrolyte reabsorption in the kidneys. This increases the excretion of sodium and chloride, which leads to an increased flow of urine.

Q: How quickly can I expect Vasoretic to start lowering my blood pressure?

A: Official regulatory documents indicate that antihypertensive activity has been seen as early as one hour after the dose is taken. The peak blood pressure reduction is often observed approximately four to six hours after administration.

Q: Is it common to feel dizzy or lightheaded when starting Vasoretic?

A: Dizziness is reported in official documents as the most frequent adverse experience in controlled trials. The medication can also cause orthostatic effects, such as a temporary drop in blood pressure when standing up.

Q: How often does the dry, persistent cough side effect occur with this medication?

A: A dry, persistent cough was reported in a minority of patients in controlled trials (3.5%). Official product information notes that this is considered a class effect associated with the enalapril component.

Q: Can Vasoretic cause muscle cramps or unusual tiredness?

A: Muscle cramps and fatigue (unusual tiredness) have been reported as adverse experiences in controlled clinical trials. Should such effects become severe or concerning, a review with a healthcare professional is indicated.

Q: What is angioedema and what are the warning signs of this serious side effect?

A: Angioedema is severe swelling that may involve the face, lips, tongue, or throat. If signs of this condition occur, official guidance requires immediate medical consultation and discontinuation of the drug.

Q: What are the signs of low potassium (hypokalemia) to watch out for?

A: Official documents list symptoms that may be linked to electrolyte imbalances, such as muscle cramps, general weakness, and a fast or irregular heartbeat. These effects may indicate a change in potassium levels, which a healthcare provider may monitor.

Q: Can this medication affect blood sugar levels, especially for people with diabetes?

A: The thiazide diuretic component may alter glucose tolerance. Official warnings indicate that patients with diabetes may require adjustment of their antidiabetic drugs when taking this medication.

Q: Is there a higher risk of sun sensitivity or sunburn while taking Vasoretic?

A: Photosensitivity (increased sensitivity to sunlight) has been reported as an adverse effect associated with the hydrochlorothiazide component. Due to the potential for photosensitivity, sun protection is a necessary precaution reported in official warnings.

Q: Does Vasoretic have an impact on sexual function or performance?

A: Impotence (erectile dysfunction) and decreased libido (sexual desire) have been reported as adverse effects in clinical trials.

Q: Can Vasoretic cause stomach upset, nausea, or diarrhea?

A: Nausea and diarrhea were reported among the most frequent clinical adverse experiences in controlled trials. Other digestive issues like vomiting and abdominal pain have also been reported.

Q: Is it normal to urinate more frequently when taking this medicine?

A: The medication contains a diuretic (water pill) which is documented to increase the flow of urine. Because of this mechanism, it may result in an increased frequency of urination.

Q: Are there any known long-term side effects from using Vasoretic for many years?

A: Long-term use of the hydrochlorothiazide component has been associated with an increased risk of nonmelanoma skin cancer (basal cell and squamous cell carcinoma), according to official warnings.

Q: Can Vasoretic affect my vision or cause sudden eye pain?

A: Blurred vision is a reported adverse effect. Furthermore, the hydrochlorothiazide component is associated with a risk of conditions like acute angle-closure glaucoma, which can cause sudden eye pain.

Q: What common over-the-counter pain relievers or cold medicines interact with Vasoretic?

A: Official guidance suggests that the combination with Non-Steroidal Anti-Inflammatory Drugs (NSAIDs), such as ibuprofen, may reduce the blood pressure-lowering effect. It may also increase the risk of kidney function issues.

Q: Does Vasoretic cause changes in the body's potassium levels?

A: The medicine can affect your body's potassium levels. The diuretic component tends to reduce potassium, while the ACE inhibitor component works to block that loss, and the overall effect may result in small increases in serum potassium.

Q: Is it safe to use salt substitutes that contain potassium while taking Vasoretic?

A: Official product information states that combining Vasoretic with potassium-containing salt substitutes increases the potential risk of hyperkalemia, which is a high level of potassium in the blood. Official information indicates that due to this risk, the use of these substitutes is generally restricted.

Q: Can alcohol consumption interfere with the effectiveness or safety of Vasoretic?

A: Official documentation states that alcohol consumption can potentiate the risk of orthostatic hypotension. This effect is a documented risk of the drug that involves a drop in blood pressure when standing, which can lead to dizziness.

Q: Are there any specific concerns about taking Vasoretic with certain antidepressants?

A: Combining Vasoretic with other medicines that can lower blood pressure, such as certain antidepressants, may increase the risk of hypotensive effects. This refers to a greater chance of experiencing low blood pressure.

Q: What dietary changes, if any, are necessary while on Vasoretic?

A: The official label requires patients to avoid potassium-containing salt substitutes due to the risk of high potassium levels in the blood. There are no other specific mandatory dietary changes listed in official documents.

Q: What precautions are necessary when taking Vasoretic in very hot weather?

A: The medicine can cause photosensitivity (sun sensitivity) and dizziness upon standing (orthostatic effects). Official warnings suggest these effects, particularly dizziness, may be worsened by hot weather or dehydration.

Q: Can I take Vasoretic if I have severe diarrhea or vomiting?

A: If there is a significant loss of body fluid from severe diarrhea or vomiting, this can lead to very low blood pressure (hypotension). This situation may make it dangerous to take the medication, as noted in official warnings.

Q: Does Vasoretic contain a sulfa drug?

A: Yes, the hydrochlorothiazide component is chemically classified as a sulfonamide derivative, which is a type of sulfa drug.

Q: What are the concerns for patients with a known sulfa drug allergy?

A: Official regulatory guidance states that the medicine is contraindicated and should not be used in patients who have a known allergy to sulfonamide-derived medicines.

Q: Is Vasoretic suitable for people with pre-existing kidney problems?

A: The medication is not recommended for people with severe renal impairment (a serious form of kidney disease). This is because the diuretic component may not be effective in patients with very low kidney function.

Q: What are the potential risks if I have liver disease and take Vasoretic?

A: The use of the ACE inhibitor component can rarely cause a syndrome that starts with jaundice (yellowing of the skin) and may progress to severe hepatic necrosis (liver tissue death). Liver dysfunction has been reported as an adverse reaction.

Q: What is the official guidance on using Vasoretic during pregnancy?

A: Official documents include a Boxed Warning that use during the second and third trimesters can cause injury and death to the developing fetus. Official guidance requires the medication to be discontinued as soon as possible when pregnancy is detected.

Q: Is it safe to use Vasoretic while breastfeeding?

A: The drug is known to be excreted into human milk. Regulatory guidance states that a decision must be made to either discontinue breastfeeding or discontinue the drug, considering its importance to the mother.

Q: Is there a link between the use of Vasoretic and the risk of skin cancer?

A: Yes, long-term use of the hydrochlorothiazide component may be associated with an increased risk of nonmelanoma skin cancer, specifically basal cell and squamous cell carcinoma. This is noted in official warnings.

Q: What is the difference in action between Vasoretic (an ACE inhibitor/diuretic) and an ARB drug?

A: The enalapril component is an ACE inhibitor, which works by inhibiting the ACE enzyme, a peptidyl dipeptidase, to stop the formation of angiotensin II. An ARB (Angiotensin II Receptor Blocker) works differently by blocking the effects of angiotensin II on the cell receptors.

Q: Is it better to take the pill in the morning or at night?

A: Official information states the medication is taken once daily. Given the action of the diuretic component lasts about six to twelve hours, taking the dose earlier in the day is common.

Q: Are there specific lab tests my doctor will monitor while I am on this medication?

A: Official documents state that periodic monitoring of certain lab values is required. This monitoring typically includes serum electrolytes (like potassium) and renal function (kidney function).

Q: Is it necessary to stop taking Vasoretic before a planned surgery or dental work?

A: Regulatory warnings indicate that patients undergoing major surgery or during anesthesia may experience severe hypotension (low blood pressure) due to the enalapril component.

Q: Can Vasoretic cause changes in my mood or feeling of well-being?

A: Adverse reactions reported in official documents include changes in mental state such as depression, confusion, nervousness, and somnolence (drowsiness).

Q: What if I experience chest pain or heart palpitations after starting Vasoretic?

A: Chest pain, palpitations (feeling of irregular or rapid heartbeat), and tachycardia (fast heart rate) have been reported as adverse reactions.

Q: What is the connection between Vasoretic and the condition known as gout?

A: Gout has been reported as an adverse reaction. Furthermore, the hydrochlorothiazide component is known to increase uric acid levels, which can trigger or worsen gout in predisposed individuals.

Q: Can Vasoretic cause an allergic reaction other than angioedema?

A: Hypersensitivity reactions other than angioedema have been reported, including a rash, urticaria (hives), and severe reactions like anaphylaxis (a serious, life-threatening allergic reaction).

Q: Is there any research evidence on the long-term heart benefits of Vasoretic?

A: Dedicated studies on the long-term impact of the fixed-dose combination on major cardiovascular events are limited. Official information indicates that inferences regarding these long-term benefits are derived from extensive research on the drug's individual components (ACE inhibitors and thiazide diuretics).

Q: What is the official recommended storage temperature for Vasoretic tablets?

A: Official guidelines state that the tablets should be stored at 20 C to 25 C (68 F to 77 F). The official storage conditions require the tablets to be protected from moisture.

How should Vasoretic be stored and disposed of?

How to Store and Dispose of Vaseretic Tablets

The storage and disposal instructions for Vaseretic (enalapril maleate-hydrochlorothiazide) are specified in official labeling to maintain the product's stability and safety.

Storage Requirements

Vaseretic tablets must be stored at Controlled Room Temperature, which is defined as a range between 20 C to 25 C (68 F to 77 F). Storage is permitted to temporarily exceed this range, between 15 C and 30 C (59 F and 86 F). It is a mandatory requirement to keep Vaseretic out of the reach of children to prevent accidental ingestion.

Disposal Instructions

Official instructions require that any unused or expired Vaseretic tablets must be disposed of according to local regulations. This ensures the product is discarded through approved pharmaceutical or environmental waste pathways as determined by regional governance.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Vasoretic found in:

A-Z Index: